Immutep Finalizes Patient Enrollment in Vital Breast Cancer Trial
Immutep Completes Patient Enrollment for AIPAC-003 Trial
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced an important milestone in its clinical research endeavors. The company has successfully completed patient enrollment for the Phase II segment of the AIPAC-003 clinical trial, focusing on metastatic breast cancer treatments.
Overview of the AIPAC-003 Clinical Trial
The AIPAC-003 trial, also known as Active Immunotherapy and Paclitaxel, is specifically aimed at patients facing challenges with metastatic hormone receptor-positive (HR+), HER2-negative/low, or triple-negative breast cancer. All participants enrolled in this trial have previously undergone endocrine therapy, including CDK4/6 inhibitors, and are in need of alternative treatment options.
Trial Details and Objectives
This Phase II trial enrolled 65 patients, who have been randomized to receive either 30mg or 90mg doses of eftilagimod alpha, commonly referred to as 'efti', combined with paclitaxel. The goal is to identify the optimal biological dose that aligns with the FDA's innovative Project Optimus initiative aimed at improving cancer treatment efficacy.
Importance for Patients and Future Innovations
The significance of the AIPAC-003 trial cannot be overstated, particularly for those patients who have exhausted traditional treatment avenues. By targeting specific cancer types and enhancing the body’s immune response through groundbreaking therapies like eftilagimod alpha, Immutep is at the forefront of a shift toward personalized cancer treatment.
Looking Ahead: Updates and Further Information
As data begins to be collected, cleaned, and analyzed, Immutep is committed to providing timely updates regarding the trial's progress and findings. Being part of such a significant clinical trial not only reflects the company’s dedication to innovation but also its commitment to patient care.
About Immutep
Immutep is a pioneering biotechnology company specializing in developing unique LAG-3 immunotherapies for cancer and autoimmune conditions. With a diverse portfolio focused on Lymphocyte Activation Gene-3 (LAG-3), Immutep seeks to coax the immune system into more effectively targeting cancer cells, while also recognizing the importance of modulating immune responses where necessary. This dual approach not only aims to improve patient outcomes but also strives to create sustainable value for shareholders.
Commitment to Innovative Treatment Solutions
The company is dedicated to harnessing its core competencies to deliver cutting-edge treatment options to patients facing grave health challenges. By leveraging scientific advancements and incorporating patient feedback, Immutep stands poised to make a significant impact in the oncology field.
Company Contacts
For media inquiries, Australian investors and media can contact Catherine Strong at Sodali & Co. at +61 (0)406 759 268. U.S. media can direct their queries to Chris Basta, the Vice President of Investor Relations and Corporate Communications, at +1 (631) 318 4000.
Frequently Asked Questions
What is the AIPAC-003 trial?
The AIPAC-003 trial is a Phase II clinical study designed to evaluate the efficacy of eftilagimod alpha combined with paclitaxel for patients with metastatic breast cancer.
How many patients are involved in the trial?
A total of 65 patients with metastatic breast cancer have been enrolled in the AIPAC-003 trial.
What types of breast cancer are being targeted?
The trial targets metastatic hormone receptor-positive (HR+), HER2-negative/low, and triple-negative breast cancer cases.
What is eftilagimod alpha?
Eftilagimod alpha, or 'efti', is a novel immunotherapy designed to enhance the immune response against cancer cells.
How can I learn more about Immutep's developments?
For ongoing updates and information, interested parties can visit Immutep's official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Assessing Sirius XM Holdings: Is It a Smart Investment Now?
- Toyota Delays North American EV Production Amid Sales Decline
- XTM Inc. Welcomes New CFO Following Trading Resumption
- Exciting Transformations Await Life Sciences Events in 2025
- Growth and Future of Buy Now Pay Later in U.S. Market
- HII to Announce Q3 Results and Insightful Earnings Call
- Empowering Future Leaders: Attend FBLA's Career Conferences
- Manufacturing Resilience: A Deep Dive into Talent Trends
- Unlocking Cyber Resilience: Join Our ASM Webinar with Criminal IP
- Cyberimpact Enhances Marketing with New Landing Pages Feature
Recent Articles
- Heartfelt Rescue of Critically Endangered Gorilla Infant
- Worksport Expands Sales Strategy to U.S. Government Agencies
- Strategic Leadership Moves at J.S. Held for Future Growth
- Customer Data Platform Market: A Bright Future Ahead
- Projecting the Growth of the Femtech Market Through 2031
- ZK International's $4.47 Million Contract Enhances Infrastructure
- Exploring Generational Views on Online Fraud: Veriff's Insights
- On Holding's Bright Future: Analysts Increasing Price Targets
- Endoscopy Devices Market Growth and Innovations Ahead
- PDS Biotechnology Achieves Positive Trial Results; Buy Rating Upheld
- Skyharbour Resources Secures Key Uranium Projects for Growth
- TotalEnergies: Strategic Insights on Growth and Shareholder Returns
- iCAD Showcases ProFound Cloud Innovations at JFR 2024 Event
- Savara's Bright Future: Analyst Insights and Market Developments
- Allarity Therapeutics Bolsters Leadership to Drive Innovation
- Thailand's Finance Minister Advocates for Rate Cuts to Boost Economy
- Evaxion Biotech's AI-Immunology Platform Sets New Standards
- Geopolitical Climate and Market Resilience Amid Tensions
- SCYNEXIS Highlights Promising Antifungal Data at IDWeek Event
- LeddarTech Innovates Automotive Safety with Cutting-Edge AI
- Fenbo Holdings Reports Strong Financial Performance for H1 2024
- Pacira BioSciences Marks Milestone with New J-Code for EXPAREL
- Carpenter Technology Corporation's Upcoming Earnings Call Insights
- Exploring the Next Big Breakout Restaurant Stocks
- Spectral AI Revolutionizes Wound Care with New Technology
- D-BOX Technologies Announces Departure of Board Member
- How to Enhance Retirement Income with Social Security Strategies
- Exploring Opportunities: CMC Metals' Groundbreaking Projects
- Marjorie Taylor Greene's Strategic Stock Acquisitions Revealed
- Constellation Brands Unveils Strong Second Quarter Results
- FirstService to Reveal Q3 Financial Outcomes Soon
- FTI Consulting's Upcoming Financial Results and Insights
- Employee Election Results for AKVA Group ASA Board Members
- U.S. Economy Demonstrates Strong Resilience Amid Global Challenges
- Nykredit Realkredit A/S Adjusts Coupon Rates on Bonds
- DexCom, Inc. Shareholder Alert: Important Class Action News
- Alphamin Reports Strong Q3 FY2024 Results with Dividend Boost
- Class Action Insights for Extreme Networks Shareholders
- Hellas Gold and Eldorado Gold Support Scholarship for Greek Students
- Arch Biopartners Secures Debt Settlement Through Unit Issuance
- Urgent Update for Investors in Super Micro Computer Stocks
- Costamare Inc. Elects New Class II Directors at Stockholder Meeting
- Acadia Healthcare Faces Securities Investigation and Losses
- Ford Motor Company Faces Legal Challenges: What You Need to Know
- Automotive Collision Repair Market Set for Robust Growth
- Altius Minerals Highlights Q3 2024 Project Generation Growth
- D-BOX Technologies Inc. Board Resignation and Future Steps
- Innovative Digital Solutions Tackling Healthcare Staffing Issues
- Elevai Biosciences Secures New Patents for Innovative Treatment
- IBAT Launches Innovative Loan Marketplace for Community Banks